KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Notes Payables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Notes Payables for 17 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Notes Payables rose 8.33% to $1.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 8.33% increase, with the full-year FY2025 number at $1.3 million, up 8.33% from a year prior.
  • Notes Payables was $1.3 million for Q4 2025 at Bio-Rad Laboratories, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.7 million in Q3 2021 to a low of $448000.0 in Q3 2022.
  • A 5-year average of $926947.4 and a median of $519000.0 in 2023 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: tumbled 99.59% in 2021, then skyrocketed 169.15% in 2025.
  • Bio-Rad Laboratories' Notes Payables stood at $489000.0 in 2021, then decreased by 4.91% to $465000.0 in 2022, then grew by 7.53% to $500000.0 in 2023, then skyrocketed by 140.0% to $1.2 million in 2024, then rose by 8.33% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Notes Payables are $1.3 million (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025).